Novo Nordisk Flaunts Tresiba To Outsmart Sanofi’s Lantus In India
This article was originally published in PharmAsia News
After widening the gap with competitors in the insulin market by a huge margin, Novo Nordisk is preparing to launch Tresiba and take a shot at the long-acting basal insulin market, a stronghold preserved by Sanofi globally. Will Tresiba firmly establish Novo Nordisk as the unquestionable insulin leader?
You may also be interested in...
FDA is requesting data from a dedicated cardiovascular outcomes trial before approving the ultra-long-acting insulins Tresiba and Ryzodeg. News of the regulatory setback caused a 13% drop in the company’s stock price on Feb. 11.
Novo Nordisk Expects Strong Patient Benefits To Propel Victoza Sales In India But Will Pricing Get In The Way?
MUMBAI - Enthused by better-then-expected performance of its latest GLP-1 agonist Victoza (liraglutide) in the U.S., Novo Nordisk hopes that its new offering will find wide acceptance among Indian diabetologists and endocrinologists as it gears up for a nationwide launch. In addition to the U.S., Canada, India and E.U., Victoza has been introduced in a short span of time in 11 countries and will soon be available in Japan
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.